Stratos Investment Management LLC Purchases 6,309 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Stratos Investment Management LLC increased its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 22.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,806 shares of the biopharmaceutical company's stock after purchasing an additional 6,309 shares during the period. Stratos Investment Management LLC's holdings in Bristol Myers Squibb were worth $2,062,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of BMY. Vanguard Group Inc. increased its holdings in shares of Bristol Myers Squibb by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 189,944,516 shares of the biopharmaceutical company's stock worth $10,743,262,000 after buying an additional 1,373,209 shares during the last quarter. Capital International Investors boosted its stake in shares of Bristol Myers Squibb by 7.5% during the 4th quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock worth $2,593,940,000 after purchasing an additional 3,218,865 shares during the period. Geode Capital Management LLC boosted its stake in shares of Bristol Myers Squibb by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 44,391,247 shares of the biopharmaceutical company's stock worth $2,505,967,000 after purchasing an additional 1,187,231 shares during the period. Norges Bank purchased a new position in shares of Bristol Myers Squibb during the 4th quarter worth about $1,989,525,000. Finally, Ameriprise Financial Inc. boosted its stake in shares of Bristol Myers Squibb by 59.9% during the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock worth $1,814,341,000 after purchasing an additional 12,011,983 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP Samit Hirawat purchased 4,250 shares of the stock in a transaction dated Friday, April 25th. The shares were acquired at an average cost of $47.58 per share, with a total value of $202,215.00. Following the purchase, the executive vice president directly owned 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.09% of the stock is currently owned by company insiders.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $46.50 on Tuesday. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. The stock has a market capitalization of $94.63 billion, a P/E ratio of 17.42, a P/E/G ratio of 1.39 and a beta of 0.36. The company's fifty day moving average is $47.69 and its two-hundred day moving average is $53.50. Bristol Myers Squibb Company has a 1 year low of $39.50 and a 1 year high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The business had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. During the same period in the prior year, the company posted ($4.40) EPS. The business's revenue for the quarter was down 5.6% on a year-over-year basis. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be paid a dividend of $0.62 per share. The ex-dividend date of this dividend is Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.33%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Wall Street Analysts Forecast Growth

BMY has been the subject of several research reports. The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 price objective (down from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Argus raised shares of Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Finally, UBS Group lowered their price objective on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of "Hold" and a consensus price target of $58.00.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.